

From: [Hackman, Blaine](#)
To: [Director PTABDecision Review](#)
Cc: [Zolgensma-Dechert-All IPRs](#); john.livingstone@finnegan.com; jeffrey.smyth@finnegan.com; amanda.murphy@finnegan.com; [Helm, Katherine](#); [Antons, Amanda](#)
Subject: IPR2023-01044 and IPR2023-01045 | Patent Owner's Withdrawal of Its Requests for Rehearing by the Director
Date: Thursday, February 15, 2024 3:08:13 PM

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Honorable Director Vidal,

On January 23, 2024, Patent Owner Genzyme Corporation requested Director Reviews of the Decisions Granting Institution of IPR2023-01044 and IPR2023-01045. The parties have reached a settlement, and accordingly Patent Owner requests that its Requests for Director Review be withdrawn for both IPR2023-01044 and IPR2023-01045. Petitioners Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation have confirmed that they will not oppose Patent Owner's requests to withdraw its Requests for Director Review.

The parties are available for a conference call at the Director's convenience should a discussion be required.

Respectfully submitted,

/Blaine M. Hackman/
Reg. No. 67,479
Attorney of Record for Patent Owner of Genzyme Corporation

Blaine M. Hackman
Counsel

Dechert LLP
+1 917 388 8306 Direct
+1 646 552 5261 Mobile
blaine.hackman@dechert.com
dechert.com

This e-mail is from Dechert LLP, a law firm, and may contain information that is confidential or privileged. If you are not the intended recipient, do not read, copy or distribute the e-mail or any attachments. Instead, please notify the sender and delete the e-mail and any attachments. Thank you.

IPR2023-01044
IPR2023-01045
Ex. 3101